One Christmas Eve, Ron Womack found himself in the emergency room, complaining of chest pains.
The ER doctor ran an electrocardiogram test on him, saw it was normal, and told Womack to follow up with a cardiologist. After more than a month of costly tests, including a stress ECG, echo-cardiogram, and an invasive angiogram, Womack was diagnosed with a severe blockage of his coronary arteries, which required a quintuple bypass.
It’s possible that, with HeartSciences’ new diagnostic device, MyoVista, Womack could have avoided some of the tests and wait time between symptom and diagnosis. Womack, in fact, was a participant in MyoVista field research. Now, the R&D activities are complete and, thanks to a $12 million capital raise that took place early in 2017, the device is moving into production, and will soon be launched.
North Texas-based HeartSciences, formerly known as Heart Test Laboratories, spent the last several years testing and developing MyoVista, a non-invasive medical device designed as a front-line diagnostic tool that is more effective than the standard ECG. It’s the first product for the company founded in 2008 to develop low-cost tools for the early detection of heart disease.
The idea behind MyoVista is that early, effective screening can lead to quicker diagnosis, fewer costly tests, and better patient outcomes. The device can be used, and interpreted by general practitioners and emergency room physicians. With a 15.6-inch high-resolution touchscreen display, it includes operational features similar to a tablet device.
MAKING A MOVE
The company, currently operating in Westlake is relocating its corporate headquarters to Granite Place I at 550 Reserve St. at Southlake Town Square. HeartSciences announced this week that it signed a lease for 4,634 square feet of office space in the newly finished building. Steve Thelen and Kimarie Ankenbrand with JLL represented the tenant, while Burson Holman and Avery Bush with Granite Properties self-represented the landlord.
“Granite Place I provides an ideal real estate solution that allows the innovators at HeartSciences to continue their mission of developing medical devices that enable accurate, affordable screening for early detection of heart disease,” Thelen said in a release.